Sugi Predict

Sugi Predict / Compounds / SCHEMBL262928

SCHEMBL262928

SCHEMBL262928

COC(=O)c1nc(C)ccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.48
▸ IRAK4 Q9NWZ3 1/20 0.47
▸ S1PR4 O95977 1/20 0.46
▸ ALDH1A1 P00352 9/20 0.43
▸ KDM4E B2RXH2 9/20 0.43
▸ HSD17B10 Q99714 4/20 0.43
▸ HPGD P15428 4/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ CFTR P13569 2/20 0.43
▸ GAA P10253 4/20 0.42
▸ GLA P06280 2/20 0.42
▸ PKM P14618 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ TP53 P04637 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775059 1.00 GRM5 (0.54) GRM5NPSR1IRAK4S1PR4ALDH1A1
SCHEMBL31282770 0.82 ALDH1A1 (0.49) GRM5ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6896843 0.82 ALDH1A1 (0.49) GRM5ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL2372967 0.81 NPSR1 (0.52) GRM5NPSR1S1PR4ALDH1A1KDM4E
SCHEMBL14634345 0.81 GRM5 (0.47) GRM5NPSR1IRAK4ALDH1A1KDM4E
SCHEMBL31663021 0.80 NPSR1 (0.47) NPSR1IRAK4ALDH1A1KDM4EHSD17B10
SCHEMBL320590 0.80 NPSR1 (0.47) NPSR1IRAK4ALDH1A1KDM4EHSD17B10
SCHEMBL4257399 0.80 NPSR1 (0.47) NPSR1IRAK4ALDH1A1KDM4EHSD17B10
SCHEMBL31345137 0.80 NPSR1 (0.47) NPSR1IRAK4ALDH1A1KDM4EHSD17B10
SCHEMBL30775571 0.80 NPSR1 (0.47) NPSR1IRAK4ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346603-A1 TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIKAVATION THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-20250270213-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-08-28 — — US disclosed
EP-4511373-A1 PI3K? INHIBITORS Synnovation Therapeutics, Inc. (US) 2025-02-26 — — EP disclosed
EP-3676261-B1 SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS CHRONOS THERAPEUTICS LTD (GB) 2024-12-18 — — EP disclosed
WO-2024081345-A1 BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS ONKURE, INC. (US) 2024-04-18 — — WO disclosed
CN-111315734-B Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists 克罗诺斯治疗有限公司 2024-03-08 — — CN disclosed
WO-2023230262-A1 TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-11-30 — — WO disclosed
WO-2023205680-A1 PI3Kα INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-10-26 — — WO disclosed
US-11660293-B2 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists CHRONOS THERAPEUTICS LIMITED (GB) 2023-05-30 — — US disclosed
US-11660293-B2 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists CHRONOS THERAPEUTICS LIMITED (GB) 2023-05-30 — — US disclosed
WO-2010072722-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-07-01 — — WO disclosed
WO-2010072722-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-07-01 — — WO disclosed
US-20100168131-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-07-01 — — US disclosed
US-20100168131-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-07-01 — — US disclosed
WO-2010063662-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0] HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 — — WO disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 — — US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 — — US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 — — US disclosed
WO-2010063663-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 — — WO disclosed
WO-2010063663-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168131-A1 NOVEL COMPOUNDS HTR3B, HNMT, TPMT GRM5 312/4885NPSR1 203/4885IRAK4 3567/4885
US-20250346603-A1 TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIK3CA, PIK3CD, PIK3CB GRM5 3517/4885NPSR1 4844/4885IRAK4 582/4885
US-20100144760-A1 NOVEL COMPOUNDS HTR3B, HTR1B, HTR2B GRM5 163/4885NPSR1 120/4885IRAK4 3367/4885
US-20250270213-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 GRM5 2876/4885NPSR1 4827/4885IRAK4 594/4885
US-11660293-B2 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists HCRTR2, HCRTR1, NPY1R GRM5 482/4885NPSR1 9/4885IRAK4 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.